VectorBuilder Biotechnology is a Hong Kong-based gene delivery company offering scientific research and clinical carrier CRO, gene-drug CDMO, and gene delivery IP out-licensing. Its platform covers the full field of life science and gene medicine, and the company has delivered more than 1.2 million gene delivery solutions to over 4,000 research institutes and pharmaceutical companies worldwide. Its gene-drug CRO and CDMO projects span North America, Europe, Japan and South Korea. In October 2022 the company raised CNY410M in a Series C round led by Legend Capital. Proceeds are intended to upgrade and expand its gene delivery R&D and production technology platform, accelerate global business presence, and boost R&D in life sciences and genetic medicines. The company was founded by Dr. Bruce Lahn.

Total raised

$57M

Funding rounds

1

Latest round

Series C

Latest activity

Oct 2022